Release date: 13 January 2005
Promoter – Financial Intermediary
Orion CorporationLocation
Description
The project comprises numerous initiatives for discovery and production of pharmaceuticals in selected core therapeutic areas (central nervous system, cardiovascular diseases and hormonal therapies).
Objectives
The Project would support the company’s RDI expenditure aimed at producing proprietary original pharmaceutical innovations. It corresponds to EU policy and the objectives of the Bank’s Innovation 2010 Initiative to bolster investments in human capital, and industrial innovation and research.
Comments
i2i – Research, development and innovative investments (RDI), as well as creation and diffusion of new technologies.
Sector(s)
Proposed EIB finance (Approximate amount)
Loan of up to EUR 150 million
Total cost (Approximate amount)
EUR 300 million
Environmental aspects
The expected increase in R&D activities will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres, etc. An EIA therefore is not required by EU Directive 97/11/EC.
Procurement
The promoter, as a private company is not bound by EU Directives on procurement. R&D activities are generally carried out by the promoter research staff. Procedures for procuring specialized equipment and external services will be varified during appraisal.
Status
Signed - 15/12/2006
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).